Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Amgen

Status and phase: Completed; Phase 2; Phase 1

Conditions: Oncology; Metastatic Colorectal Cancer; Colon Cancer; Rectal Cancer; Colorectal Cancer

Treatments: Drug: Conatumumab; Drug: Panitumumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00630786

20060332

2007-004722-25 (EudraCT Number)

Details and patient eligibility

About

This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.

Full description

This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.

The objective for Part 1 is to identify a tolerable dose of conatumumab in combination with panitumumab based on the incidence of dose-limiting toxicities in patients with Metastatic Colorectal Cancer.

The objective for Part 2 is to evaluate the objective response rate stratified by Kirsten Rat Sarcoma Virus Oncogene (KRAS) status (wild-type versus mutant) in patients with Metastatic Colorectal Cancer treated with the combination of panitumumab and conatumumab (tolerable dose identified in part 1).

Enrollment: 53 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum

• Radiographically documented disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) during or following treatment with fluoropyrimidine, irinotecan, and/or oxaliplatin chemotherapy for Metastatic Colorectal Cancer. Progressive disease must be documented during or ≤ 6 months after the last dose of the most recent chemotherapy regimen prior to enrollment.

• At least 1 uni-dimensionally measurable lesion measuring ≥ 20 mm in one dimension per modified RECIST. Lesion must not be chosen from a previously irradiated field, unless there has been documented disease progression in that field after irradiation and prior to enrollment. All sites of disease must be evaluated.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Available archived paraffin-embedded tumor tissue from the primary tumor or metastasis for submission to the central laboratory

• Man or woman ≥ 18 years of age at the time of enrollment

• Hematologic function within the following limits:

  • Absolute neutrophil count (ANC) > 1.0 x 10^9 cells/L
  • Platelets ≥ 100 x 10^9/L

• Renal function within the following limits:

  • Creatinine < 2.0 mg/dL

• Hepatic function within the following limits:

  • Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN) (≤ 5 x ULN if liver metastases)
  • Alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases)
  • Bilirubin ≤ 2 x ULN

• Metabolic function within the following limits:

  • Amylase ≤ 2 x ULN
  • Lipase ≤ 2 x ULN
  • Magnesium ≥ lower limit of normal

• Negative pregnancy test ≤ 72 hours before enrollment (for woman of childbearing potential only)

• Must have received 1, 2, or 3 prior chemotherapy regimens for Metastatic Colorectal Cancer

• Competent to comprehend, sign, and date the independent ethics committee/institutional review board (IEC/IRB) approved written informed consent

Exclusion criteria

• History of other primary cancer, unless:

  • Curatively resected non-melanomatous skin cancer
  • Curatively treated cervical carcinoma in situ
  • Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≥ 5 years before enrollment

• Prior treatment with anti-epidermal growth factor receptor (EGFr) inhibitors (eg, cetuximab, erlotinib, gefitinib), unless treatment was received in the adjuvant setting ≥ 6 months before enrollment

• Use of systemic chemotherapy and radiotherapy ≤ 30 days before enrollment

• Use of prior anti-tumor therapies with a short serum half-life (less than 1 week) including prior experimental agents or approved anti-tumor small molecules ≤ 30 days before enrollment

• Use of anti-tumor therapies with a longer serum half-life (eg, bevacizumab) including prior experimental or approved protein/antibodies ≤ 42 days before enrollment

• Any investigational agent or therapy ≤ 30 days before enrollment

• Known allergy or hypersensitivity to any component of panitumumab and/or AMG 655

• History of or known presence of central nervous system (CNS) metastases

• History of interstitial lung disease (eg, pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan

• Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment

• Active inflammatory bowel disease or other active bowel disease causing chronic diarrhea (defined as ≥ Common Terminology Criteria for Adverse Events [CTCAE] grade 2 [CTCAE version 3.0])

• Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic hepatitis B infection

• Any co-morbid disease or condition that could increase the risk of toxicity (eg, significant ascites, significant pleural effusion)

• Any uncontrolled concurrent illness (eg, infection, bleeding) or history of any medical condition that may interfere with the interpretation of the study results

• Major surgical procedure (requiring general anesthesia) ≤ 28 days or minor surgical procedure (excluding central venous catheter placement) ≤ 14 days before enrollment. Patients must have recovered from surgery related toxicities.

• Other investigational procedures are excluded

• Patient is currently pregnant or breast feeding

• Man or woman of childbearing potential who is not willing to use adequate contraceptive precautions during treatment and for 6 months (for women) or 1 month (for men) after the last investigational product administration. Adequate contraceptive precautions includes double barrier contraceptive methods (eg, diaphragm and condom) or abstinence.

• Previously enrolled into this study

• Patient unwilling or unable to comply with study requirements

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

53 participants in 1 patient group

Panitumumab plus conatumumab

Experimental group

Description:

Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.

Treatment:

Drug: Panitumumab

Drug: Conatumumab